RHY rhythm biosciences limited

15.4%

6.0¢

@boranoReview of Phase Four of the National Bowel Cancer...

First 3 Last

Share
Profile

Follow
josiejow37

359 Posts.

113

30/01/23

22:26

Post #: 65960042
Share

Originally posted by josiejow37: ↑

I've posted this link previously, however, posting again in case it got lost in the thread.

Review of Phase Four of the National Bowel Cancer Screening Program Evaluation Report
September 2021
https://gcphn.org.au/wp-content/uploads/2022/06/NBCSP-Review-Report.pdf

The report provides an extremely thorough analysis of the various benefits and shortcomings of the current screening program...as we know there are a lot of shortcomings! The economic analysis is also very interesting. There is a preference for greater involvement of GPs and nurses.

Overall, the report is loaded with detailed information that indicates that a simple, low-cost, accurate screening blood test would be most welcome, and would fit into existing frameworks.

Overseas countries are mentioned whereby there is greater participation from GPs and nurses with regard to overseeing the test and triaging patients with positive results.

Combining the mail-out approach with opportunistic provision and return of kits through GPs, pharmacies and/or other trusted practitioners is suggested as an improvement. This is interesting because Colostat would also involve GP involvement.

Wait time for colonoscopy in Australia is flagged as a whopping 51 days on average, because the system is clogged up with unnecessary procedures, a huge problem for all involved. The associated potential harms of colonoscopy are also mentioned.

Disadvantages of the current program for disabled, First Nations and rural communities is detailed.

Page 34 section headed "The efficacy of emerging testing technologies should continue to be monitored" is of particular interest.

Rhythm Biosciences is listed twice (page 93 and page 109) as an organisation that was consulted by Delottes in preparing the report.

Expand

@borano

Review of Phase Four of the National Bowel Cancer Screening Program:

"In any decision to transition to a new test type, it is important that the test is approved by the
Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a
cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity,
as compared with the current iFOBT."

RHY Price at posting: $1.00 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

KGD

Kula picks up unexplored niobium play in Malawi, with surface samples logged

THL

Tourism Holdings says Liberation Day tariffs smashed US RV demand

OSL

OncoSil wraps up recruitment for key pancreatic cancer trial

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

Trump chides Powell as Goldman call for calm. The RBA must be nervous

Week 27 Wrap: 40% China tariffs?; ASX +10% FY25; US Amazon price spike

NMG

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

DMP

Is Domino's a steal after -25% plunge?

HotCopper Highlights, Week 27: G8 scalped, Domino’s drops the box, Gemlife brief hype & more

AII

Inside the Depths of Panasqueira: A Legacy Carved in Rock

First 3 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 6.0¢		Change 0.008(15.4%)		Mkt cap ! $17.04M

Open	High	Low	Value	Volume
5.2¢	6.0¢	5.2¢	$21.32K	381.7K

Buyers (Bids)

No.	Vol.	Price($)
3	198929	5.6¢

Sellers (Offers)

Price($)	Vol.	No.
6.0¢	248871	4

View Market Depth

No.	Vol.	Price($)
3	198929	0.056
1	98789	0.055
1	20507	0.054
1	97	0.051
6	547611	0.050

Price($)	Vol.	No.
0.060	248871	4
0.062	43127	1
0.065	5377	1
0.075	88927	1
0.080	38871	2

Last trade - 15.42pm 04/07/2025 (20 minute delay)

RHY (ASX) Chart

@boranoReview of Phase Four of the National Bowel Cancer...

Kula picks up unexplored niobium play in Malawi, with surface samples logged

Tourism Holdings says Liberation Day tariffs smashed US RV demand

OncoSil wraps up recruitment for key pancreatic cancer trial

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

Trump chides Powell as Goldman call for calm. The RBA must be nervous

Week 27 Wrap: 40% China tariffs?; ASX +10% FY25; US Amazon price spike

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

Is Domino's a steal after -25% plunge?

HotCopper Highlights, Week 27: G8 scalped, Domino’s drops the box, Gemlife brief hype & more

Inside the Depths of Panasqueira: A Legacy Carved in Rock

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

@boranoReview of Phase Four of the National Bowel Cancer...

Top Stories

Kula picks up unexplored niobium play in Malawi, with surface samples logged

Tourism Holdings says Liberation Day tariffs smashed US RV demand

OncoSil wraps up recruitment for key pancreatic cancer trial

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

Trump chides Powell as Goldman call for calm. The RBA must be nervous

Week 27 Wrap: 40% China tariffs?; ASX +10% FY25; US Amazon price spike

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

Is Domino's a steal after -25% plunge?

HotCopper Highlights, Week 27: G8 scalped, Domino’s drops the box, Gemlife brief hype & more

Inside the Depths of Panasqueira: A Legacy Carved in Rock

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News